PFE $Pfizer (PFE.US)$ appears to be doing everything right. ...

PFE $Pfizer (PFE.US)$ appears to be doing everything right. They have a solid stable of approved drugs, a strong pipeline, and billions of dollars in COVID related vaccines and treatments. They are using the money to add on promising biotechs to support their drug development efforts. Keeping their solid dividend is also a plus as they originally were going to reduce it by what VTRS $Viatris (VTRS.US)$ was going to pay after acquiring PFE's generic business. $60 a share seems like a conservative estimate in 22.